# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Edward White maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target ...
Needham analyst Gil Blum maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $12 to $6.
Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardio...
Shares of G1 Therapeutics are down after release of Phase 3 trial results for trilaciclib in TNBC.
The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market. G1 is Sufficiently...
Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.